Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2021 08:30 ET | Source: Veru Inc.

Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients

—Sabizabulin is a novel oral agent with both anti-viral and anti-inflammatory activities— —Sabizabulin treatment reduced mortality in hospitalized COVID-19 patients at high risk for Acute Respiratory...
May 12, 2021 06:30 ET | Source: Veru Inc.

Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues

-- First Patient to Be Enrolled this Week in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients-- --New Drug Application Accepted for Review by FDA for...
May 05, 2021 08:30 ET | Source: Veru Inc.

Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021

MIAMI, May 05, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
April 28, 2021 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call on May 12th

MIAMI, April 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
April 21, 2021 08:30 ET | Source: Veru Inc.

Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress

MIAMI, April 21, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
March 09, 2021 08:30 ET | Source: Veru Inc.

Veru to Present at the Oppenheimer 31st Annual Healthcare Conference

MIAMI, March 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
March 08, 2021 08:30 ET | Source: Veru Inc.

Veru Exploring Strategic Alternatives for its Legacy Female Health Business

MIAMI, March 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast...
March 02, 2021 08:30 ET | Source: Veru Inc.

Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference

MIAMI, March 02, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
March 01, 2021 08:30 ET | Source: Veru Inc.

Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)

– Veru completes expedited end of Phase 2 trial meeting with FDA – – FDA agrees that Phase 2 clinical findings suggest a clinically meaningful benefit for the use of VERU-111 in hospitalized COVID-19...
February 23, 2021 08:30 ET | Source: Veru Inc.

Veru Submits New Drug Application for Proprietary TADFIN for BPH

--TADFIN™, Tadalafil 5mg and Finasteride 5mg formulated capsule, for daily oral dosing to improve compliance-- --Administration of Tadalafil and Finasteride is more effective than Finasteride alone...